Señales en vivo de ALACT.PA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 11:35):

Stats
Volumen de hoy	1.66M
Volumen promedio	58 523.00
Capitalización de mercado	5.29M
EPS	€0 ( 2023-10-26 )
Próxima fecha de ganancias	( €0 ) 2024-05-10
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.200
ATR14	€0.0220 (6.47%)

Volumen Correlación

Largo: -0.11 (neutral)

Corto: -0.46 (neutral)

Signal:(37.645) Neutral

Groupe Actiplay SA Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Groupe Actiplay SA Correlación - Moneda/Commodity

0.67
( moderate )

0.68
( moderate )

0.00
( neutral )

0.57
( weak )

-0.53
( weak negative )

0.02
( neutral )

Groupe Actiplay SA Finanzas

Annual	2022
Ingresos:	€0
Beneficio Bruto:	€-86 000.00 (0.00 %)
EPS:	€-1.580

FY	2022
Ingresos:	€0
Beneficio Bruto:	€-86 000.00 (0.00 %)
EPS:	€-1.580

FY	2021
Ingresos:	€0.00
Beneficio Bruto:	€0.00 (0.00 %)
EPS:	€-0.120

FY	2020
Ingresos:	€0.00
Beneficio Bruto:	€0.00 (0.00 %)
EPS:	€-0.726

Financial Reports:

No articles found.

Groupe Actiplay SA

Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.